Last update 01 Nov 2024

USL-311

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
CXCR4
Mechanism
CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists)
Therapeutic Areas
NeoplasmsNervous System DiseasesOther Diseases
Active Indication
Glioblastoma
Inactive Indication
Advanced Malignant Solid NeoplasmRecurrent Glioblastoma
Originator Organization
Ligand Pharmaceuticals, Inc.Ligand Pharmaceuticals, Inc.
Active Organization
Ligand Pharmaceuticals, Inc.Ligand Pharmaceuticals, Inc.Upsher-Smith Laboratories LLCUpsher-Smith Laboratories LLC
Inactive Organization
Proximagen Group Plc
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC24H34N6O
InChIKeyXNUNVQKARNSSEO-UHFFFAOYSA-N
CAS Registry1373268-67-7

Related

2
Clinical Trials associated with USL-311
EUCTR2015-004214-14-ES / Not yet recruitingPhase 1/2
A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects with Relapsed/Recurrent Glioblastoma Multiforme (GBM).
NCT02765165 / TerminatedPhase 1/2
A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects With Relapsed/Recurrent Glioblastoma Multiforme (GBM)
100 Clinical Results associated with USL-311
Login to view more data
100 Translational Medicine associated with USL-311
Login to view more data
100 Patents (Medical) associated with USL-311
Login to view more data
100 Deals associated with USL-311
Login to view more data

External Link

KEGGWikiATCDrug Bank
---
DB15265

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 3
ES
Proximagen Group Plc
01 Apr 2016
Advanced Malignant Solid NeoplasmPhase 3
US
Proximagen Group Plc
01 Apr 2016
Recurrent GlioblastomaPhase 3
US
Proximagen Group Plc
01 Apr 2016
Recurrent GlioblastomaPhase 3
ES
Proximagen Group Plc
01 Apr 2016
GlioblastomaPhase 2-
Upsher-Smith Laboratories LLCUpsher-Smith Laboratories LLC
-
GlioblastomaPhase 2-
Ligand Pharmaceuticals, Inc.Ligand Pharmaceuticals, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free